Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis

Diabetes and Metabolism

Volumn 33, Issue 3, 2007, Pages 213-219

  Hammana, I ^a,b   Malet, A ^a   Costa, M ^a   Brochiero, E ^b   Berthiaume, Y ^a,b   Potvin, S ^a   Chiasson, J L ^a,b   Coderre, L ^a,b   Rabasa Lhoret, R ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adiponectin; Cystic fibrosis; Diabetes; Inflammation; Insulin sensitivity

Indexed keywords

ADIPONECTIN; ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; INSULIN; PANCREAS ENZYME;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS INSUFFICIENCY; PREVALENCE; RADIOIMMUNOASSAY;

ADIPONECTIN; ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL; CYSTIC FIBROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FIBRINOGEN; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; LIPOPROTEINS, HDL; MALE; REFERENCE VALUES; TRIGLYCERIDES;

EID: 34249910644     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2007.01.004     Document Type: Article

References (39)

1. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
2. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA 98 (2001) 2005-2010
3. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002) 1288-1295
4. Combs T.P., Berg A.H., Obici S., et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108 (2001) 1875-1881
5. Lacquemant C., Vasseur F., Lepretre F., et al. [Adipocytokins, obesity and development of type 2 diabetes]. Med Sci (Paris) Spec No (2005) 10-18
6. Haluzik M., Parizkova J., and Haluzik M.M. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol. Res. 53 (2004) 123-129
7. Brichard S.M., Delporte M.L., and Lambert M. Adipocytokines in anorexia nervosa: a review focusing on leptin and adiponectin. Horm. Metab. Res. 35 (2003) 337-342
8. St Pierre D.H., Faraj M., Karelis A.D., et al. Lifestyle behaviours and components of energy balance as independent predictors of ghrelin and adiponectin in young non-obese women. Diabetes Metab. 32 (2006) 131-139
9. Costa M., Potvin S., Berthiaume Y., et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab. 31 (2005) 221-232
10. Diagnosis and classification of diabetes mellitus. Diabetes Care 28 Suppl 1 (2005) S37-S42
11. Moran A., Hardin D., Rodman D., et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res. Clin. Pract. 45 (1999) 61-73
12. Costa M., Potvin S., Beauregard G., et al. Mesurer l'insulinorésistance en pratique quotidienne et en recherche. Sang Thrombose Vaisseaux 9 (2004) 455-460
13. UK cystic fibrosis trust diabetes working group. Management of cystic fibrosis related diabetes. In: Bromley (Ed). Cystic fibrosis trust (2004), Cystic Fibrosis Trust, Kent, UK
14. Kopp H.P., Krzyzanowska K., Mohlig M., et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int. J. Obes. (Lond) 29 (2005) 766-771
15. Zietz B., Herfarth H., Paul G., et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett. 545 (2003) 103-104
16. Tacke F., Wustefeld T., Horn R., et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J. Hepatol. 42 (2005) 666-673
17. Sidlova K., Skalicka V., Kotaska K., et al. Serum alpha-glutathione S-transferase as a sensitive marker of hepatocellular damage in patients with cystic fibrosis. Physiol. Res. 52 (2003) 361-365
18. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55 (2006) 1537-1545
19. Lanng S., Thorsteinsson B., Roder M.E., et al. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clin. Endocrinol. (Oxf.) 41 (1994) 217-223
20. Cucinotta D., De Luca F., Gigante A., et al. No changes of insulin sensitivity in cystic fibrosis patients with different degrees of glucose tolerance: an epidemiological and longitudinal study. Eur. J. Endocrinol. 130 (1994) 253-258
21. Holl R.W., Heinze E., Wolf A., et al. Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis. Eur. J. Pediatr. 154 (1995) 356-361
22. Hardin D.S., LeBlanc A., Lukenbough S., et al. Insulin resistance is associated with decreased clinical status in cystic fibrosis. J. Pediatr. 130 (1997) 948-956
23. Hardin D.S., LeBlanc A., Para L., et al. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes 48 (1999) 1082-1087
24. Austin A., Kalhan S.C., Orenstein D., et al. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J. Clin. Endocrinol. Metab. 79 (1994) 80-85
25. Hardin D.S., LeBlanc A., Marshall G., et al. Mechanisms of insulin resistance in cystic fibrosis. Am. J. Physiol. Endocrinol. Metab. 281 (2001) E1022-E10E8
26. Moran A., Pyzdrowski K.L., Weinreb J., et al. Insulin sensitivity in cystic fibrosis. Diabetes 43 (1994) 1020-1026
27. Ahmad T., Nelson R., and Taylor R. Insulin sensitivity and metabolic clearance rate of insulin in cystic fibrosis. Metabolism 43 (1994) 163-167
28. Tofe S., Moreno J.C., Maiz L., et al. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur. J. Endocrinol. 152 (2005) 241-247
29. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86 (2001) 1930-1935
30. Kim M.J., Maachi M., Debard C., et al. Increased adiponectin receptor-1 expression in adipose tissue of impaired glucose-tolerant obese subjects during weight loss. Eur. J. Endocrinol. 155 (2006) 161-165
31. Abbasi F., Chang S.A., Chu J.W., et al. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290 (2006) R139-R144
32. Moriconi N., Kraenzlin M., Muller B., et al. Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis. J. Clin. Endocrinol. Metab. 91 (2006) 1586-1590
33. Pellme F., Smith U., Funahashi T., et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 52 (2003) 1182-1186
34. Cruz M., Garcia-Macedo R., Garcia-Valerio Y., et al. Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care 27 (2004) 1451-1453
35. Bastard J.P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17 (2006) 4-12
36. Frystyk J., Tarnow L., Hansen T.K., et al. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48 (2005) 1911-1918
37. Housova J., Anderlova K., Krizova J., et al. Serum adiponectin and resisting concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J. Clin. Endocrinol. Metab. 90 (2005) 1366-1370
38. Wilson D.C., and Pencharz P.B. Nutrition and cystic fibrosis. Nutrition 14 (1998) 792-795
39. Orenstein D.M., Hovell M.F., Mulvihill M., et al. Strength vs. aerobic training in children with cystic fibrosis: a randomized controlled trial. Chest 126 (2004) 1204-1214